Results 151 to 160 of about 586,644 (327)

Treatment Options, Clinical Outcome (Quality of Life) and Cost Benefit (Quality-adjusted Life Year) in Varicose Vein Treatment [PDF]

, 2012
Damian Kelleher, Tristan Lane, I J Franklin, Alun H. Davies   +3 more
openalex   +1 more source

The MMP‐9/TIMP‐1 Ratio and Concentrations of Osteopontin Are Elevated in Cerebrospinal Fluid of People With Multiple Sclerosis and Decrease After Autologous Hematopoietic Stem Cell Transplantation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives To evaluate the utility of cerebrospinal fluid (CSF) biomarkers—matrix metalloproteinase‐9 (MMP‐9), tissue inhibitor of metalloproteinases‐1 (TIMP‐1), the MMP‐9/TIMP‐1 ratio, and osteopontin (OPN)—as indicators of blood–brain barrier (BBB) integrity and disease activity in people with relapsing–remitting multiple sclerosis (pwMS ...
Ivan Pavlovic, Ida Erngren, Kim Kultima, Anders Larsson, Malin Müller, Anna Wiberg, Joachim Burman   +6 more
wiley   +1 more source

Additional file 4: of Using the Fatigue Severity Scale to inform healthcare decision-making in multiple sclerosis: mapping to three quality-adjusted life-year measures (EQ-5D-3L, SF-6D, MSIS-8D)

, 2019
Elizabeth Goodwin, Annie Hawton, Colin Green   +2 more
openalex   +2 more sources

Proportion of Acceptable Symptom State Nearly Tripled With Improvements in Patient‐Reported Outcomes for All Symptom State Subgroups: A Registry Study of More Than 15,000 Patients With Osteoarthritis in Digital Education and Exercise Therapy

Arthritis Care &Research, EarlyView.
Objective This study investigated trajectories of patient acceptable symptom state (PASS) among participants of digital education and exercise therapy for knee and hip osteoarthritis. Methods A longitudinal observational study among individuals aged at least 40 years who participated in the digital program.
Ali Kiadaliri, L. Stefan Lohmander, Amanda E. Nelson, Leif E. Dahlberg   +3 more
wiley   +1 more source

Gain in Quality-adjusted Life-years in Patients with Rheumatoid Arthritis During 1 Year of Biological Therapy: A Prospective Study in Clinical Practice [PDF]

, 2013

openalex   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source

Gender differences in added benefit of catheter-based renal denervation for resistant hypertension: model-based estimation of unadjusted and quality-adjusted life year gains in males and females [PDF]

, 2013
Jan B. Pietzsch, B.P. Geisler, Murray Esler   +2 more
openalex   +1 more source

Annual cost of illness and quality-adjusted life year losses in the United States due to 14 foodborne pathogens.

Journal of Food Protection, 2012
S. Hoffmann, Michael B. Batz, J. Garrett Morris   +2 more
semanticscholar   +1 more source

Treating lupus nephritis patients to lupus low disease activity reduces renal relapse and preserves long‐term kidney function

Arthritis Care &Research, Accepted Article.
Objective Lupus low disease activity state (LLDAS) is a validated treatment target in systemic lupus erythematosus (SLE) but limited studies have explored the role of LLDAS in lupus nephritis (LN). This study aims to investigate the frequency and predictors of LLDAS attainment, and its benefit on LN relapse and renal function preservation in patients ...
Chak Kwan Cheung, Desmond YH Yap, KL Lee, Philip H Li, Iris YK Tang, Chak Sing Lau, Shirley CW Chan   +6 more
wiley   +1 more source

Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran

Applied Health Economics and Health Policy, 2018
K. Lankarani, Sulmaz Ghahramani, N. Moradi, H. Shahraki, F. Lotfi, B. Honarvar   +5 more
semanticscholar   +1 more source